The Costa Rica Ministry of Health approved Nutriband Inc.’s line of kinesiology tapes on March 18, 2026, opening a new distribution channel in Central America.
The approval follows a February 17 distribution agreement with Innomedica CCB S.A., which oversaw and financed the regulatory process. The kinesiology line, which includes the AVERSA product range and mosquito repellent patches, will now be available for import and sale in Costa Rica, extending Nutriband’s reach beyond the United States.
While the approval expands geographic reach, it is expected to generate only modest revenue compared to the company’s contract manufacturing segment. For the nine months ended October 31, 2025, Nutriband reported a net loss of $7.26 million, with revenue primarily driven by its Pocono Pharmaceuticals contract manufacturing business. The sale of a 90% interest in Pocono Pharma to EarthVision Bio for $5 million in December 2025 was intended to fund the AVERSA Fentanyl program.
Nutriband’s core focus remains the development of its AVERSA™ abuse‑deterrent transdermal technology, particularly the AVERSA™ Fentanyl patch. The company is pursuing a streamlined 505(b)(2) NDA pathway for the product. The Costa Rica approval demonstrates regulatory compliance capabilities that could support future product launches in other markets.
The kinesiology tape approval represents a regulatory milestone that adds a new revenue stream, but it is unlikely to materially alter the company’s financial outlook in the short term. The approval underscores Nutriband’s ability to navigate regulatory processes and may serve as a foundation for expanding its product portfolio beyond the United States.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.